Sanofi

Sanofi is a global healthcare company focused on the research, development, manufacture, and marketing of therapeutic solutions. Its portfolio spans immunology and inflammation, rare diseases, neurology, oncology, and vaccines. Key vaccine offerings include pediatric vaccines for poliomyelitis, pertussis, haemophilus influenzae type b (Hib), respiratory syncytial virus protection, and hexavalent combination vaccines covering hepatitis A, typhoid, yellow fever, and rabies. Sanofi also engages in numerous collaborations, such as with Exscientia to develop up to 15 novel small-molecule drugs for oncology and immunology, and with Kymera Therapeutics for protein degrader therapies targeting IRAK4 in immune-inflammatory diseases. Additionally, it partners with Teva Pharmaceuticals to co-develop and co-commercialize TEV'574 for ulcerative colitis and Crohn's disease.

Sanofi is listed on the NasdaqGS exchange under the ticker symbol SNY. Its shares trade in US dollars (USD). The company is headquartered in France, but its US listing allows investors to trade its stock in American markets.

Sanofi operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This means it is a pharmaceutical company that develops, produces, and markets a wide range of drugs and therapeutic products. As a general drug manufacturer, Sanofi covers multiple therapeutic areas including immunology, oncology, rare diseases, neurology, and vaccines, distinguishing it from companies focused on a single disease area.

Sanofi is headquartered in France, as indicated by its country of incorporation. While the company is based in Europe, it serves global markets, with a significant presence in the United States as evidenced by its listing on the NasdaqGS. Its therapeutic solutions are marketed worldwide, and its collaborations with companies such as Exscientia (UK), ABL Bio (South Korea), Innate Pharma (France), and Denali Therapeutics (US) highlight its international reach in research and development.

Sanofi has a broad network of collaborations and license agreements to expand its pipeline. Notable partnerships include a collaboration with Exscientia to develop up to 15 novel small-molecule drugs for oncology and immunology, and with Innate Pharma for a cell engager program targeting B7-H3. It also works with Kymera Therapeutics on protein degrader therapies targeting IRAK4 for immune-inflammatory diseases, and with Nurix Therapeutics on protein degradation therapies. Additionally, Sanofi collaborates with Denali Therapeutics to treat systemic inflammatory diseases like ulcerative colitis, and with Adagene for antibody-based therapies. In genome editing, it partners with Scribe Therapeutics. Furthermore, Sanofi has a co-development and co-commercialization agreement with Teva Pharmaceuticals for TEV'574, a treatment for ulcerative colitis and Crohn's disease, and a co-promotion service agreement with Provention Bio.